TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023

Rhea-AI Summary

CAMBRIDGE, Mass., Feb. 08, 2023 – TCR² Therapeutics Inc. (Nasdaq: TCRR) announced a management presentation at the SVB Securities Global Biopharma Conference (virtual) on February 14, 2023, at 1:00 PM ET. This event will provide an update on the company’s progress in developing novel T cell therapies for solid tumors.

A live webcast is accessible via the company’s Investors page, with an archived replay available for 30 days post-presentation.

TCR² Therapeutics focuses on innovative T cell therapies, using their proprietary TRuC®-T cells to target and eliminate cancer cells effectively.

CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will present a company update at the SVB Securities Global Biopharma Conference (virtual) on Tuesday, February 14, 2023 at 1:00 PM ET.

A live webcast of the presentation will be available on the Investors page of the Company’s website at investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics
TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.

Media Contact:
Kathy Vincent
kathy@kathyvincent.com

Investor Contact:
Eric Sullivan
Chief Financial Officer
eric.sullivan@tcr2.com

FAQ

When will TCR² Therapeutics present at the SVB Securities Global Biopharma Conference?

TCR² Therapeutics will present on February 14, 2023, at 1:00 PM ET.

How can I watch TCRR's presentation at the biopharma conference?

You can watch the live webcast on the Investors page of TCR² Therapeutics' website.

What is TCR² Therapeutics' main focus?

TCR² Therapeutics focuses on developing innovative T cell therapies for patients with solid tumors.

What technology does TCR² use for its cancer therapies?

TCR² utilizes their proprietary TRuC®-T cells to target and destroy cancer cells.

Will there be a replay of TCRR's presentation available?

Yes, an archived replay will be available for at least 30 days following the presentation.